Recursion Pharmaceuticals, Inc. (RXRX) Stock Forecast & Price Prediction 2025, 2030, 2040, and 2050
Stay updated on Recursion Pharmaceuticals, Inc. (RXRX) stock with short-term forecast for year 2025 and long-term price prediction for 2025 - 2050. Access historical performance, see analyst ratings, and follow the latest Recursion Pharmaceuticals, Inc. news and developments.
1 Month Prediction
$13.60 [220.65%]
3 Month Prediction
$13.14 [210.02%]
6 Month Prediction
$11.32 [167.09%]
1 Year Prediction
$9.28 [118.88%]
3 Year Prediction
$1.00 [-76.42%]
5 Year Prediction
$1.00 [-76.42%]
About Recursion Pharmaceuticals, Inc.
Recursion Pharmaceuticals, Inc., founded in 2013 by Christopher Gibson, Dean Li, and Blake Borgeson, is a clinical-stage biotechnology company headquartered in Salt Lake City, Utah. The company decodes biology to industrialize drug discovery by integrating technological innovations across biology, chemistry, automation, data science, and engineering.
Recursion's main platform, the Recursion Operating System (OS), maps and navigates trillions of biological and chemical relationships within the Recursion Data Universe. This map can speed up the process of finding treatments.
The company's clinical pipeline includes several programs:
- REC-994: An orally bioavailable small molecule in development for the treatment of symptomatic cerebral cavernous malformation (CCM).
- REC-2282: A potential treatment for neurofibromatosis type 2.
- REC-3964: Aimed at preventing recurrent Clostridioides difficile infection.
Recursion Pharmaceuticals, Inc. (RXRX) Historical Performance
IPO Date
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) went public on 16 April, 2021.
Change
Since inception, RXRX has fallen from $26.36 to $4.24, a massive -83.92% decrease since 2021.
Historical Highs and Lows
In the past 4 years, the stock reached a high of $36.50 and a low of $4.24.
52 Week Range
$4.06
$12.36
The current price $4.24 is near the 52-week low, which means that the stock is underbought.
RXRX Stock Price History
Based on RXRX stock's historical price data, this table shows how the stock has performed in the last 4 years. Since 2021, the RXRX stock has fallen from $6.12 - $11.84 to $4.24 - $7.51, which is down -76.27%. Currently, the stock follows downward trend.
Here, we have calculated stock range of RXRX, indicating the highs and lows for each year, the average price based on the daily closing prices each year, and the change% from the average price.
| Year | Stock Price | Avg Price | Change% | Year Change |
|---|---|---|---|---|
| 2022 | $6.12 - $11.84 | $8.97 | -64.94 | 1 Year Change |
| 2023 | $4.77 - $14.12 | $8.05 | -68.53 | 2 Year Change |
| 2024 | $6.32 - $13.46 | $8.22 | -67.87 | 3 Year Change |
| 2025 | $4.24 - $7.51 | $6.07 | -76.27 | 4 Year Change |
RXRX Price Performance
6-Month Performance
RXRX stock dropped by 40.03% in the last six months.
1-Year Performance
The stock has trended downwards by 48.79% in the past year.
3-Year Performance
In the last 3 years, the stock has plummeted by 30.72%.
5-Year Performance
In the last 5 years, the stock has gone down by 87.31%.
According to Recursion Pharmaceuticals, Inc.'s historical data, below graph gives us the exact picture of how the RXRX stock has performed year-over-year. Here, Each bar on the graph represents a particular year that illustrates how the stock's price changed from one year to the next.
YoY Performance
In the last five years, the stock has shown positive growth in 1 year and a decline in 2 years.
2022
54.99% ↓
2023
27.89% ↑
2024
31.44% ↓
NOTE: Green bars indicate that the stock has risen compared to the previous year, while red bars show that the stock has fallen.
Recursion Pharmaceuticals, Inc. (RXRX) Financials & Stock Analysis
Total Revenue
Quarterly Revenue: $4.51 M (Q4)
Revenue for Q4 ending 31st December, 2024 decreased 82.70% compared to Q3 ending 30th September, 2024.
Annual Revenue: $58.49 M (1Y)
Revenue for trailing 12 months decreased 0.00% year over year from 31st December, 2024.
Market Capitalization
Recursion Pharmaceuticals, Inc. has a market capitalization of $1.70B, which places RXRX in the small-cap category.
Fundamental Analysis
EPS: $-0.53 (Q4), $nan (1Y)
EPS increased 55.88% since last quarter, and decreased nan% since last year.
Net Income: $-178.91 M (Q4), $-463.66 M (1Y)
Net Income increased 86.67% since last quarter, and increased 41.33% since last year.
Free Cash Flow: $-117.08 M (Q4), $-376.22 M (1Y)
Free Cash Flow increased 83.55% since last quarter, and increased 25.27% since last year.
Net Profit Margin: -3965.99% (Q4), -792.75% (1Y)
Net Profit Margin increased 979.29% since last quarter, and increased 41.33% since last year.
Below, we have listed 12 key indicators for Fundamental analysis for RXRX stock. These indicators help you understand Recursion Pharmaceuticals, Inc.'s financial health, earnings and growth potential, and make a decision if the stock is a good long-term investment or not.
|
|
Technical Analysis
Here, we have listed 5 key indicators for Technical Analysis for RXRX stock. These indicators help investors study past price movements and trading volumes to forecast future price changes, and find the right time when to buy, sell or hold the stock.
| Technical Indicators | Value |
|---|---|
| SMA20 | $5.98 |
| SMA50 | $7.16 |
| SMA200 | $7.08 |
| RSI | 17.42 |
| Beta | 1.00 |
SMA20 > Current Price
This signals RXRX stock is in short-term bearish momentum.
SMA50 > Current Price
This signals RXRX stock is in mid-term bearish momentum.
SMA200 > Current Price
This signals RXRX stock is in long-term bearish momentum.
Sentiment Based on Technical Analysis
Based on 8 technical analysis indicators, the overall sentiment for RXRX stock is Bearish. Out of all indicators, 3 indicates bullish signals, 6 signals bearish trends and 0 gives neutral trends. The RXRX stock forecast was last updated on 05 April, 2025.
Recursion Pharmaceuticals, Inc. (RXRX) Stock Price Prediction and Forecast
According to short-term forecast, the stock is expected to rise to $12.09 by the end of 2025, and can reach around $13.88 to $7.09 in 2026. And, the long-term forecast suggests that the stock may further drop to $3.59 - $0.85 in 2028, and $1.38 - $1.22 by 2031. So, the RXRX stock shows a strong upward trend in the next several years.
Short-term RXRX Stock Price Prediction & Forecast
| Date | Forecasted Price | Change% |
|---|---|---|
| 2025-05 | $13.60 | 220.75% |
| 2025-06 | $12.58 | 196.7% |
| 2025-07 | $13.14 | 209.91% |
| 2025-08 | $12.21 | 187.97% |
| 2025-09 | $11.61 | 173.82% |
| 2025-10 | $11.32 | 166.98% |
| 2025-11 | $9.41 | 121.93% |
| 2025-12 | $12.09 | 185.14% |
In 2025, the RXRX stock price is expected to fluctuate between $9.41 and $13.6. According to the monthly forecast, the stock could rise to $12.09 by December 2024. If compared to the RXRX's current price, the stock could gain 185.14% by the end of this year.
Long-term RXRX Stock Price Prediction & Forecast
| Year | Year Start | Year Mid | Year End | Change% |
|---|---|---|---|---|
| 2026 | $13.88 | $9.72 | $7.09 | 67.22% |
| 2027 | $8.26 | $12.24 | $4.10 | -3.3% |
| 2028 | $3.59 | $4.61 | $0.85 | -79.95% |
| 2029 | $1.14 | $1.29 | $0.71 | -83.25% |
| 2030 | $0.74 | $1.06 | $1.08 | -74.53% |
| 2031 | $1.38 | $1.25 | $1.22 | -71.23% |
| 2032 | $1.15 | $1.09 | $1.43 | -66.27% |
| 2033 | $0.82 | $0.26 | $0.67 | -84.2% |
| 2034 | $0.77 | $1.49 | $0.57 | -86.56% |
| 2035 | $0.42 | $1.08 | $0.33 | -92.22% |
| 2036 | $1.41 | $1.08 | $0.69 | -83.73% |
| 2037 | $1.08 | $1.41 | $1.10 | -74.06% |
| 2038 | $0.99 | $1.28 | $1.30 | -69.34% |
| 2039 | $1.10 | $0.88 | $1.05 | -75.24% |
| 2040 | $0.82 | $0.66 | $1.21 | -71.46% |
| 2041 | $1.39 | $0.78 | $0.99 | -76.65% |
| 2042 | $1.40 | $0.75 | $0.83 | -80.42% |
| 2043 | $0.81 | $0.28 | $0.82 | -80.66% |
| 2044 | $0.75 | $1.21 | $0.44 | -89.62% |
| 2045 | $0.89 | $1.40 | $1.31 | -69.1% |
| 2046 | $0.68 | $1.06 | $0.88 | -79.25% |
| 2047 | $0.97 | $1.45 | $0.68 | -83.96% |
| 2048 | $1.05 | $0.73 | $0.86 | -79.72% |
| 2049 | $0.49 | $0.85 | $1.34 | -68.4% |
| 2050 | $0.91 | $1.19 | $1.08 | -74.53% |
| 2051 | $1.08 | $1.18 | $0.53 | -87.5% |
Recursion Pharmaceuticals, Inc. (RXRX) Stock Price Prediction & Forecast 2025
At the start of 2025, the RXRX stock was at $7.24. Today, it is trading at $4.24, which is -41.44% decrease from price at the beginning of the year. By the end of this year, you can expect the stock to reach to $12.09 by December 2025 with a 185.14% change.
Recursion Pharmaceuticals, Inc. (RXRX) Stock Price Prediction & Forecast 2026 - 2030
In the next five years, there will be a significant depreciation in the RXRX stock. During this period, the RXRX's price is forecasted to shift from $13.88 to $1.08, which is -92.22% loss.
In 2026, the stock would possibly open at $13.88, descends to $9.72 by mid-year, and wraps up at $7.09, reflecting a 67.33% increase from today's price. Further moving to 2030, the stock can kick off the year at $0.74, drop to $1.06 by mid-year, and finish at $1.08, which is -74.48% change from current price.
Recursion Pharmaceuticals, Inc. (RXRX) Stock Price Prediction & Forecast 2031 - 2040
During this period, the stock would move from $1.38 to $1.21, which is down -71.30%
In 2031, we can expect RXRX to fluctuate between $1.22 and $1.38, a shift indicating a -71.30% loss by year-end compared to current price. And Until 2040, RXRX can likely vary from $0.82 to $1.21. By the end of 2040, the stock could record a -71.38% fall from today's stock price.
Recursion Pharmaceuticals, Inc. (RXRX) Stock Price Prediction & Forecast 2041 - 2050
According to long-term forecast, the RXRX stock can see an a downturn from $1.39 to $1.08 in this period. In 2041, the stock can experience a low of $0.78 by mid-year, closing the year at $0.99. This results in a -81.57% decrease from today.
Moving towards the end of 2050, RXRX is projected to open the year at $0.91. The stock may peak to $1.19 during mid-year and finish the year at $1.08. Compared to the stock's current price, this translates to an overall loss of -74.47% by 2050.
Become a member
Get the latest news right in your inbox. We never spam!
RXRX Competitors
| Ticker | Company | Market Cap | Price | 1m Change | Forecast |
|---|---|---|---|---|---|
| APVO | Aptevo Therapeutics Inc. | - | $1.99 | 71.55% ▲ | -49.75 ▼ |
| CORT | Corcept Therapeutics Incorporated | - | $114.22 | 0.00% ▼ | $0.09 ▲ |
| GLTO | Galecto, Inc. | - | $6.65 | 51.83% ▲ | $32.48 ▲ |
| RNAZ | TransCode Therapeutics, Inc. | - | $1.38 | -30.31% ▼ | -27.53 ▼ |
| CRVO | CervoMed Inc. | - | $6.91 | 208.48% ▲ | $257.27 ▲ |
Last updated Apr 05 at 9 PM
RXRX : Buy, Sell Or Hold?
Analyst Ratings
Based on 7 analysts, 1 rated as a strong buy, 0 recommended a buy, 6 suggested a hold, 0 advised a sell, and 0 indicated a strong sell.So, according to analyst ratings, the recommendation for RXRX stock is Hold.Expert Analysis
According to RXRX short-term and long-term forecast, Recursion Pharmaceuticals, Inc. shares are projected to go down by 74.53%, and reach a value of $1.08 per share by 2050.
As per technical analysis, indicators show a Bearish sentiment, while Fear & Greed Index stands at 57.142857142857146, which signals Greed. Also, RXRX has recorded 6/30 green days, which reflects a 26.08695652173913% positivity rate with a price volatility of 0.05%.
Plus, Price-to-Earnings (P/E) ratio of 0 suggests that RXRX stock is undervalued. So, Based on RXRX prediction and analysis, it may be the best time to hold RXRX stock right now.
Disclaimer: Stock predictions, forecasts and price targets provided for "RXRX” are solely for informational and educational purposes and should not be treated as investment or financial advice. Always conduct your own research or consider consulting with a financial advisor before making any investment decisions.